HC Wainwright Comments on Lipocine FY2027 Earnings

Posted by on Sep 24th, 2026

Lipocine Inc. (NASDAQ:LPCN – Free Report) – Investment analysts at HC Wainwright issued their FY2027 EPS estimates for Lipocine in a research note issued to investors on Monday, September 21st. HC Wainwright analyst Y. Chen expects that the specialty pharmaceutical company will post earnings per share of ($1.03) for the year. HC Wainwright currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Lipocine’s current full-year earnings is ($1.54) per share.

Lipocine (NASDAQ:LPCN – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.08. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%.The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million.

LPCN has been the topic of a number of other reports. Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Lipocine in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Lipocine has a consensus rating of “Hold” and a consensus target price of $4.00.

Check Out Our Latest Research Report on Lipocine

Lipocine Trading Down 1.9%

Shares of NASDAQ:LPCN opened at $2.12 on Tuesday. The stock has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $2.99. The stock has a market capitalization of $17.47 million, a price-to-earnings ratio of -1.19 and a beta of 0.47. Lipocine has a 12-month low of $1.81 and a 12-month high of $12.37.

Institutional Trading of Lipocine

Several institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its stake in shares of Lipocine by 57.5% in the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Lipocine during the first quarter valued at $185,000. Exome Asset Management LLC purchased a new stake in shares of Lipocine during the first quarter valued at $486,000. Persistent Asset Partners Ltd bought a new stake in Lipocine in the 4th quarter worth about $567,000. Finally, Seven Fleet Capital Management LP bought a new stake in Lipocine in the 1st quarter worth about $998,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

(Get Free Report)

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.

Featured Articles

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.